Perfluorohexyloctane ophthalmic solution - Novaliq

Drug Profile

Perfluorohexyloctane ophthalmic solution - Novaliq

Alternative Names: NOV 03; Novatears

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novaliq
  • Class Fluorocarbons; Small molecules
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dry eyes

Most Recent Events

  • 09 Nov 2017 Chemical structure added
  • 09 Nov 2017 Novaliq plans a phase II trial for Dry eyes in December 2017 (NCT03333057)
  • 02 Nov 2017 Preclinical trials in Dry eyes in USA (Ophthalmic) (Novaliq website, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top